We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
226
Ridgewood Investments
New Jersey
$645K -$16.7K -602 -2%
CIBC Asset Management
227
CIBC Asset Management
Ontario, Canada
$638K +$348K +12,537 +108%
CAM
228
Cresset Asset Management
Illinois
$636K -$83.8K -3,022 -11%
PRC
229
Pearl River Capital
Michigan
$635K -$1.29M -46,531 -66%
NSEDCP
230
NJ State Employees Deferred Compensation Plan
New Jersey
$633K – – –
VIM
231
Vinva Investment Management
Australia
$629K +$322K +11,627 +97%
CIBC World Market
232
CIBC World Market
Ontario, Canada
$624K +$219K +7,895 +50%
KeyBank National Association
233
KeyBank National Association
Ohio
$621K +$652K +23,533 New
MC
234
Machina Capital
France
$602K +$406K +14,651 +179%
DF
235
Donoghue Forlines
Massachusetts
$593K +$47.7K +1,719 +8%
RJFSA
236
Raymond James Financial Services Advisors
Florida
$591K +$65.5K +2,363 +12%
RIA
237
Regal Investment Advisors
Michigan
$558K +$103K +3,700 +21%
Prudential Financial
238
Prudential Financial
New Jersey
$556K +$83.2K +3,000 +17%
CWM
239
CIBC World Markets
New York
$540K +$137K +4,928 +32%
ACM
240
Aubrey Capital Management
United Kingdom
$536K -$143K -5,160 -17%
HIM
241
Hillsdale Investment Management
Ontario, Canada
$531K – – –
LA
242
LBP AM
France
$528K +$555K +20,019 New
Creative Planning
243
Creative Planning
Kansas
$527K -$475K -17,131 -46%
Verition Fund Management
244
Verition Fund Management
Connecticut
$526K -$39.7K -1,431 -7%
Stifel Financial
245
Stifel Financial
Missouri
$524K +$335K +12,095 +155%
MGP
246
Metis Global Partners
California
$517K +$168K +6,065 +45%
Pathstone Holdings
247
Pathstone Holdings
New Jersey
$515K +$2.11K +76 +0.4%
FTDI
248
First Trust Direct Indexing
Massachusetts
$502K -$72.6K -2,619 -12%
BF
249
BOK Financial
Oklahoma
$483K +$859 +31 +0.2%
M&T Bank
250
M&T Bank
New York
$474K +$13.4K +483 +3%
8 9
10
11 12

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.